Clinical Trials /

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

NCT04246177

Description:

The purpose of this study is to evaluate the efficacy and safety of lenvatinib and pembrolizumab in combination with TACE versus TACE plus oral and intravenous (IV) placebos in participants with incurable, non-metastatic hepatocellular carcinoma (HCC). The primary hypotheses are that pembrolizumab plus lenvatinib in combination with TACE is superior to placebo plus TACE with respect to progression-free survival (PFS) and overall survival (OS).

Related Conditions:
  • Hepatocellular Carcinoma
Recruiting Status:

Recruiting

Phase:

Phase 3

Trial Eligibility

Document

Title

  • Brief Title: Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
  • Official Title: A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012)

Clinical Trial IDs

  • ORG STUDY ID: 7902-012
  • SECONDARY ID: 2019-002345-37
  • SECONDARY ID: MK-7902-012
  • SECONDARY ID: LEAP-012
  • SECONDARY ID: E7080-G000-318
  • NCT ID: NCT04246177

Conditions

  • Carcinoma, Hepatocellular

Interventions

DrugSynonymsArms
LenvatinibMK-7902, E7080, LENVIMA®Lenvatinib plus Pembrolizumab plus TACE
PembrolizumabMK-3475, KEYTRUDA®Lenvatinib plus Pembrolizumab plus TACE
Oral PlaceboOral Placebo plus IV Placebo plus TACE
IV PlaceboOral Placebo plus IV Placebo plus TACE

Purpose

The purpose of this study is to evaluate the efficacy and safety of lenvatinib and pembrolizumab in combination with TACE versus TACE plus oral and intravenous (IV) placebos in participants with incurable, non-metastatic hepatocellular carcinoma (HCC). The primary hypotheses are that pembrolizumab plus lenvatinib in combination with TACE is superior to placebo plus TACE with respect to progression-free survival (PFS) and overall survival (OS).

Trial Arms

NameTypeDescriptionInterventions
Lenvatinib plus Pembrolizumab plus TACEExperimentalParticipants will receive a combination of lenvatinib, pembrolizumab, and TACE. Lenvatinib will be administered at a dose of 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight <60 kg) orally once a day during each 21-day cycle until progressive disease or unacceptable toxicity (up to 2 years [~35 cycles] or longer with Sponsor approval). Pembrolizumab will be administered via IV infusion at a dose of 400 mg once every 6 weeks (Q6W) for up to 2 years (~17 doses). Participants will undergo TACE as a background procedure of chemotherapeutic and embolic agent(s).
  • Lenvatinib
  • Pembrolizumab
Oral Placebo plus IV Placebo plus TACEActive ComparatorParticipants will receive a combination of lenvatinib-matching oral placebo, pembrolizumab-matching IV placebo, and TACE. Lenvatinib-matching oral placebo will be administered once a day during each 21-day cycle for up to 2 years (~35 cycles) or longer with Sponsor approval and pembrolizumab-matching IV placebo will be administered once every 6 weeks (Q6W) for up to 2 years (~17 doses). Participants will undergo TACE as a background procedure of chemotherapeutic and embolic agent(s).
  • Oral Placebo
  • IV Placebo

Eligibility Criteria

        Inclusion Criteria:

          -  Has a diagnosis of HCC confirmed by radiology, histology, or cytology

          -  Has HCC localized to the liver and not amenable to curative treatment

          -  Participants with Hepatitis C virus (HCV) are eligible if treatment was completed at
             least 1 month prior to starting study intervention

          -  Participants with Hepatitis B virus (HBV) are eligible as long as their virus is well
             controlled

          -  Has adequately controlled blood pressure with or without antihypertensive medications

          -  Has adequate organ function

        Exclusion Criteria:

          -  Is currently a candidate for liver transplantation

          -  Has had gastric bleeding within the last 6 months

          -  Has ascites that is not controlled with medication

          -  Has significant cardiovascular impairment within 12 months of the first dose of study
             intervention such as congestive heart failure

          -  Has a serious nonhealing wound, ulcer, or bone fracture
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Time Frame:Up to ~5 years
Safety Issue:
Description:PFS is defined as the time from randomization to the first documented progressive disease or death due to any cause, whichever occurs first. Responses are according to RECIST 1.1 as assessed by blinded independent central review (BICR).

Secondary Outcome Measures

Measure:PFS per Modified Response Evaluation Criteria in Solid Tumors (mRECIST)
Time Frame:Up to ~5 years
Safety Issue:
Description:PFS is defined as the time from randomization to the first documented progressive disease or death due to any cause, whichever occurs first. Responses are according to mRECIST as assessed by BICR.
Measure:Objective Response Rate (ORR) per mRECIST
Time Frame:Up to ~5 years
Safety Issue:
Description:ORR is defined as the percentage of participants who have a confirmed complete response (CR: disappearance of any intratumoral arterial enhancement in all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of viable [enhancement in the arterial phase] target lesions, taking as reference the baseline sum of the diameters of target lesions). Responses are according to mRECIST as assessed by BICR.
Measure:Disease Control Rate (DCR) per mRECIST
Time Frame:Up to ~5 years
Safety Issue:
Description:DCR is defined as the percentage of participants who have a best overall response of CR (disappearance of any intratumoral arterial enhancement in all target lesions), PR (at least a 30% decrease in the sum of diameters of viable [enhancement in the arterial phase] target lesions, taking as reference the baseline sum of the diameters of target lesions), or stable disease (SD). SD must be achieved at ≥6 weeks after randomization to be considered best overall response. Responses are according to mRECIST as assessed by BICR.
Measure:Duration of Response (DOR) per mRECIST
Time Frame:Up to ~5 years
Safety Issue:
Description:DOR is determined by disease assessment and is defined as the time from the first documented evidence of a response of CR (disappearance of any intratumoral arterial enhancement in all target lesions) or PR (at least a 30% decrease in the sum of diameters of viable [enhancement in the arterial phase] target lesions, taking as reference the baseline sum of the diameters of target lesions) until the first documented disease progression or death due to any cause, whichever occurs first. Responses are according to mRECIST as assessed by BICR.
Measure:Time to Progression (TTP) per mRECIST
Time Frame:Up to ~5 years
Safety Issue:
Description:TTP is defined as the time from randomization to the first documented disease progression. Responses are according to mRECIST as assessed by BICR.
Measure:Percentage of Participants Who Experience At Least One Adverse Event (AE)
Time Frame:Up to ~5 years
Safety Issue:
Description:An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experience at least one AE will be reported.
Measure:Percentage of Participants Who Experience At Least One Serious Adverse Event (SAE)
Time Frame:Up to ~5 years
Safety Issue:
Description:An SAE is an AE that results in death, is life threatening, requires or prolongs a hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is a cancer, is associated with an overdose, or is another important medical event. The percentage of participants who experience at least one SAE will be reported.
Measure:Percentage of Participants Who Experience At Least One Hepatic Event of Clinical Interest (ECI)
Time Frame:Up to ~5 years
Safety Issue:
Description:Percentage of participants with Hepatic ECIs not due to disease progression or TACE as assessed by the investigator will be reported.
Measure:Percentage of Participants Who Discontinue Study Drug Due to an AE
Time Frame:Up to ~5 years
Safety Issue:
Description:An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who discontinue study drug due to an AE will be reported.
Measure:ORR per RESCIST 1.1
Time Frame:Up to ~5 years
Safety Issue:
Description:ORR is defined as the percentage of participants who have a confirmed complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters). Responses are according to RECIST 1.1 as assessed by BICR.
Measure:DCR per RECIST 1.1
Time Frame:Up to ~5 years
Safety Issue:
Description:DCR is defined as the percentage of participants who have a best overall response of CR (disappearance of all target lesions), PR (at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters), or SD. SD must be achieved at ≥6 weeks after randomization to be considered best overall response. Responses are according to RECIST 1.1 as assessed by BICR.
Measure:DOR per RECIST 1.1
Time Frame:Up to ~5 years
Safety Issue:
Description:DOR is determined by disease assessment and is defined as the time from the first documented evidence of a response of CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters) until the first documented disease progression or death due to any cause, whichever occurs first. Responses are according to RECIST 1.1 as assessed by BICR.
Measure:TTP per RECIST 1.1
Time Frame:Up to ~5 years
Safety Issue:
Description:TTP is defined as the time from randomization to the first documented disease progression. Responses are according to RECIST 1.1 as assessed by BICR.

Details

Phase:Phase 3
Primary Purpose:Interventional
Overall Status:Recruiting
Lead Sponsor:Merck Sharp & Dohme Corp.

Trial Keywords

  • receptor tyrosine kinase inhibitor
  • programmed cell death 1 (PD-1, PD1)
  • programmed cell death ligand 1 (PD-L1, PDL1)

Last Updated

April 29, 2020